5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer

被引：0
|
作者：
Ajmal, Zainub
Shao, Jianming
Olsen, Randall
Kasparian, Saro
He, Chuan
Bernicker, Eric
Li, Zejuan
Zhang, Jun
机构：
[1] Houston Methodist Neal Canc Ctr, Houston, TX USA
[2] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX USA
[3] Houston Methodist Hosp, Houston, TX USA
[4] Houston Methodist Hosp, Dept Med Oncol, Houston, TX USA
[5] Univ Chicago, Ctr Data Intens Sci, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20563
引用
收藏
页数：1
相关论文
共 50 条
  • [41] 5-Hydroxymethylcytosine profilings in circulating cell-free DNA as diagnostic biomarkers for DLBCL
    Chen, Hangyu
    Duolikun, Maimaitiyasen
    Zhu, Hai-Chuan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [42] Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
    Pirker, Robert
    ESMO OPEN, 2018, 3 (05)
  • [43] Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
    Britt, Alec S.
    Huang, Caitlyn
    Huang, Chao H.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
    Wiest, Nathaniel
    Majeed, Umair
    Seegobin, Karan
    Zhao, Yujie
    Lou, Yanyan
    Manochakian, Rami
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
    Hendriks, Lizza E. L.
    Remon, Jordi
    Menis, Jessica
    Besse, Benjamin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2868 - 2875
  • [46] Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer
    Cho, Uiju
    Im, Soyoung
    Park, Hyung Soon
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2024, 58 (02) : 49 - 58
  • [47] Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy
    Inomata, Minehiko
    Minatoyama, Shuhei
    Takata, Naoki
    Hayashi, Kana
    Hirai, Takahiro
    Seto, Zenta
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Matsuyama, Kei
    Hayashi, Ryuji
    Matusi, Shoko
    Tobe, Kazuyuki
    ANTICANCER RESEARCH, 2024, 44 (03) : 1241 - 1245
  • [48] MONITORING IMMUNODYNAMICS IN IMMUNE CHECKPOINT INHIBITOR THERAPY FOR STAGE IIIB/IV NON-SMALL CELL LUNG CANCER
    Bento, Daniela
    Almeida, Jani Sofia
    Couceiro, Patricia
    Alves, Vera
    Santos-Rosa, Manuel
    Barata, Fernando Jose
    Rodrigues-Santos, Paulo
    Ferreira Rodrigues Figueiredo, Ana Maria
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [49] Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer
    Feifei Wei
    Tetsuro Sasada
    Genes & Immunity, 2024, 25 : 89 - 91
  • [50] Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer
    Wei, Feifei
    Sasada, Tetsuro
    GENES AND IMMUNITY, 2024, 25 (01) : 89 - 91
12345